Ejaculatory disorder by alpha-1 adrenoceptor antagonist in patients with benign prostatic hyperplasia; retrospective comparison between naftopidil and tamsulosin

Acta Urologica Japonica

Volumn 51, Issue 11, 2005, Pages 763-766

  Furuya, Ryoji ^a   Hisasue, Shinichi ^b   Ogura, Hiroshi ^a   Furuya, Seiji ^a   Masumori, Naoya ^b   Itoh, Naoki ^b   Tsukamoto, Taiji ^b  

^a Furuya Hospital   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alpha 1 adrenoceptor antagonist; Benign prostatic hyperplasia; Ejaculatory disorder

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; TAMSULOSIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EJACULATION DISORDER; HEALTH SURVEY; HUMAN; INCIDENCE; LIFE SATISFACTION; MAJOR CLINICAL STUDY; MALE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; EJACULATION; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PIPERAZINES; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RECEPTORS, ADRENERGIC, ALPHA-1; RETROSPECTIVE STUDIES; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SULFONAMIDES;

EID: 29344441862     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Djavan B and Marberger M: A meta-analysis on the efficacy and tolerability of alpha-1 adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1-13, 1999
2. Debruyne FM: Alpha blockers: are all created equal? Urology 56: 20-22, 2000
3. Lepor H, Williford WO, Barry MJ, et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335: 533-539, 1996.
4. Chapple CR: Pharmacotherapy for benign prostatic hyperplasia-the potential for alpha-1 adrenoceptor subtype-specific blockade-. Br J Urol 81: 34-47, 1998
5. Hofner K, Claes H, De Reijke TM, et al.: Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 335-341, 1999
6. Lepor H: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 36: 892-900, 1998
7. Narayan P, Tewari A, the United States 93-01 Study Group: A second phase multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 160: 1701-1706, 1998
8. Nickel JC, Narayan P, Mckay J, et al.: Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 171: 1594-1597, 2004
9. Cheah PY, Liong ML, Yuen KH, et al.: Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol 169: 592-596, 2003
10. Porpiglia F, Ghignone G, Fiori C, et al.: Nifedipine versus tamsulosin for the management of lower ureteral stones. J Urol 172: 568-571, 2004
11. Takei R, Ikegaki I, Shibata K, et al.: Naftopidil, a novel alpha-1 adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha 1-adrenoceptors. Jpn J Pharmacol 79: 447-454, 1999
12. Solomon HM, Wier PJ, Ippolito DL, et al.: Effect of prazosin on sperm transport in male rats. Reprod Toxicol 11: 627-631, 1997
13. Sadraei H, Large BJ and Hughes IE: Mechanisms involved in electrically-induced responses of rat seminal vesicles. J Pharm Pharmacol 47: 665-668, 1995
14. Shima S: Characterization of adrenergic receptors in membranes from rat seminal vesicle. Jpn J Pharmacol 61: 87-92, 1993
15. Giuliano F, Bernabe S, Droupy J, et al.: A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats. BJU Int 93: 605-608, 2004